Boston Scientific Corporation $BSX Shares Purchased by NewSquare Capital LLC

NewSquare Capital LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 3.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,191 shares of the medical equipment provider’s stock after purchasing an additional 2,341 shares during the quarter. NewSquare Capital LLC’s holdings in Boston Scientific were worth $6,680,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sound Income Strategies LLC lifted its holdings in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC acquired a new position in Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific during the 1st quarter valued at $27,000. Princeton Global Asset Management LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 145 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 2,901 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $102.24, for a total value of $296,598.24. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,467,460.16. This represents a 10.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 112,891 shares of company stock worth $11,501,887 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $98.57 on Tuesday. The stock has a market capitalization of $146.05 billion, a PE ratio of 52.71, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $83.55 and a 52 week high of $109.50. The stock has a 50 day moving average price of $100.63 and a 200 day moving average price of $102.43. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of several research reports. Barclays raised their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Leerink Partners raised their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.